The cloning of the cancer-drug-activating cells required for Nuvilex, Inc.’s future Phase III trials has begun at Inno Biologics’ cGMP facilities. Inno Biologics received four vials of frozen cells capable of converting the anticancer prodrug ifosfamide into its active cancer-killing form. The cells were successfully thawed and approximately 97% of the cells were found to be viable. The contents of the vial were tested and found to be free of bacteria, fungi, and mycoplasma.   The cloning proces...